Current views on the treatment of insulinoma

Relevance: Insulinoma is the most common hormonally active neuroendocrine tumor (NET) of the pancreas. In recent years, there has been a trend towards an increase in the incidence of NET especially insulinoma.

Aim: Summarizing and analyzing current data on various approaches to the treatment of insulinoma. Our review includes a comprehensive assessment of the advantages and disadvantages of currently available insulinoma treatment methods in comparison with past experience, as well as a review of promising methods that are not currently widely used.

Materials and methods: Analysis of literature from such databases as scientific electronic library elibrary.ru, Pubmed, Google Scholar, MedLine, Scopus and Web of Science.

Results: The most common treatment for insulinoma is surgery. For patients with high operative risk, alternative methods such as alcohol ablation, radiofrequency ablation, and tumor embolization may be used. Medications include the use of somatostatin analogues, diazoxide. The literature describes the potential benefit of the use of beta-blockers, phenytoin, glucagon, however, in clinical trials, these drugs have not demonstrated a significant effect. For the treatment of malignant and metastatically advanced insulinoma, targeted therapy (primarily Everolimus), chemotherapy, as well as embolization (including chemoembolization, radioembolization), radiofrequency ablation (RFA), microwave ablation and cryoablation, ultrasound ablation (HIFU), laser ablation, brachytherapy, irreversible electroporation are used.

Conclusion: The study of new drugs is an important task for scientists, among medications the most promising are new generations of somatostatin analogues, targeted drugs and chemotherapy drugs. The rare frequency of insulinoma makes it difficult to conduct randomized controlled trials and prospective studies. That is why physicians and scientists need to maintain close contacts with each other and take into account the experience of treating each patient with such disease, which will help develop effective treatment algorithms in the future.

1. Association of Oncologists of Russia, Russian Society of Clinical Oncology, Russian Association of Endocrinologists. Federal Clinical Guidelines for Neuroendocrine Tumors. 2022. URL: https://oncology-association.ru/wp-content/uploads/2020/09/nejrojendokrijnye_opuholi.pdf (in Russ.)

2. Yao JC, Hassan M, Phan A, et al. One Hundred Years After «Carcinoid»: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. J Clin Oncol. 2008 Jun 20; 26(18):3063–72. doi: https://doi.org/10.1200/JCO.2007.15.4377

3. Halfdanarson TR, Rabe KG, Rubin J, et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008 Oct; 19(10):1727–33. doi: https://doi.org/10.1093/annonc/mdn351

4. Muscogiuri G, Altieri B, Albertelli M, et al. Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. Endocrine. 2020; 69(2):441-450. doi: https://doi.org/10.1007/s12020-020-02331-3

5. Sotoudehmanesh R, Hedayat A, Shirazian N, et al. Endoscopic ultrasonography (EUS) in the localization of insulinoma. Endocrine. 2007; 31:238–24. doi: https://doi.org/10.1007/s12020-007-0045-4

6. Service FJ, McMAHON MM, O’Brien PC, et al. Functioning Insulinoma — Incidence, Recurrence, and Long-Term Survival of Patients: A 60-Year Study. Mayo Clin Proc. 1991 Jul; 66(7):711–9. doi: https://doi.org/10.1016/s0025-6196(12)62083-7

7. Placzkowski KA, Vella A, Thompson GB, et al. Secular Trends in the Presentation and Management of Functioning Insulinoma at the Mayo Clinic, 1987–2007. J clin endocr metab. 2009 Apr 1; 94(4):1069–73. doi: https://doi.org/10.1210/jc.2008-2031

8. Pratò S, Didonna V, Garletti F, et al. Loss of consciousness in a helicopter pilot as plausible first sign of insulinoma: a case report. Med Lav. 2022; 113(1):e2022007. doi: https://doi.org/10.23749/mdl.v113i1.12037

9. España-Gómez MN, Velázquez-Fernández D, Bezaury P, et al. Pancreatic insulinoma: a surgical experience. World J Surg. 2009; 33(9):1966-1970. doi: https://doi.org/10.1007/s00268-009-0145-9

10. Okabayashi T, Shima Y, Sumiyoshi T, et al. Diagnosis and management of insulinoma. World J Gastroenterol. 2013; 19(6):829-837. doi: https://doi.org/10.3748/wjg.v19.i6.829

11. Naples R, Thomas JD, Orabi DA, et al. A critical analysis of laparoscopic and open approaches to sporadic pancreatic insulinoma resection in the modern era. Am J Surg. 2022; 223(5):912-917. doi: https://doi.org/10.1016/j.amjsurg.2021.10.011

12. de Carbonnières A, Challine A, Cottereau AS, et al. Surgical management of insulinoma over three decades. HPB (Oxford). 2021; 23(12):1799-1806. doi: https://doi.org/10.1016/j.hpb.2021.04.013

13. Dobrindt EM, Mogl M, Goretzki PE, et al. Insulinoma in pregnancy (a case presentation and systematic review of the literature). Rare Tumors. 2021; 13:2036361320986647. Published 2021 Feb 7. doi: https://doi.org/10.1177/2036361320986647

14. Jürgensen C, Schuppan D, Neser F, et al. EUS-guided alcohol ablation of an insulinoma. Gastrointest Endosc. 2006; 63(7):1059-1062. doi: https://doi.org/10.1016/j.gie.2005.10.034

15. Zhang L, Tan S, Huang S, et al. The safety and efficacy of endoscopic ultrasound-guided ablation therapy for solid pancreatic tumors: a systematic review. Scand J Gastroenterol. 2020; 55(9):1121-1131. doi: https://doi.org/10.1080/00365521.2020.1797870

16. Paik WH, Seo DW, Dhir V, et al. Safety and Efficacy of EUS-Guided Ethanol Ablation for Treating Small Solid Pancreatic Neoplasm. Medicine (Baltimore). 2016 Jan; 95(4):e2538. doi: https://doi.org/10.1097/MD.0000000000002538

17. Qin S, Liu Y, Ning H, et al. EUS-guided lauromacrogol ablation of insulinomas: a novel treatment. Scand J Gastroenterol. 2018 May 4; 53(5):616–20. doi: https://doi.org/10.1080/00365521.2017.1402206

18. Fegrachi S, Besselink MG, van Santvoort HC, et al. Radiofrequency ablation for unresectable locally advanced pancreatic cancer: a systematic review. HPB (Oxford).2014 Feb; 16(2):119–23. doi: https://doi.org/10.1111/hpb.12097

19. Alyusuf EY, Ekhzaimy AA, Rivera JA. Radiofrequency Ablation as a Primary Therapy for Benign Functioning Insulinoma. AACE Clin Case Rep. 2020; 7(2):153–7. doi: https://doi.org/10.1016/j.aace.2020.12.003

20. Kluz M, Staroń R, Krupa Ł, et al. Successful endosonography-guided radiofrequency ablation of pancreatic insulinoma. Pol Arch Intern Med. 2020; 130(2):145-146. doi: https://doi.org/10.20452/pamw.15100

21. Rott G, Biggemann M, Pfohl M. Embolization of an Insulinoma of the Pancreas with Trisacryl Gelatin Microspheres as Definitive Treatment. Cardiovasc Intervent Radiol. 2008 May; 31(3):659–62. doi: https://doi.org/10.1007/s00270-007-9185-4

22. Giannis D, Moris D, Karachaliou GS, et al. Insulinomas: from diagnosis to treatment. A review of the literature. J BUON. 2020; 25(3):1302-1314

23. Kulke MH. Somatostatin Analogues in Neuroendocrine Tumors. J Natl Compr Canc Netw. 2016 Mar; 14(3):241–2. doi: https://doi.org/10.6004/jnccn.2016.0029

24. Stueven AK, Kayser A, Wetz C, et al. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. IJMS. 2019 Jun 22; 20(12):3049. doi: https://doi.org/10.3390/ijms20123049

25. Moris D, Ntanasis-Stathopoulos I, Tsilimigras DI, et al. Update on Surgical Management of Small Bowel Neuroendocrine Tumors. Anticancer Res. 2018; 38(3):1267-1278. doi: https://doi.org/10.21873/anticanres.12349

26. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs. 1997; 53(4):681-699. doi: https://doi.org/10.2165/00003495-199753040-00009

27. Lamberts SW, van der Lely AJ, de Herder WW, et al. Octreotide. N Engl J Med. 1996; 334(4):246-254. doi: https://doi.org/10.1056/NEJM199601253340408

28. Öberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004 Jun; 15(6):966–73. doi: https://doi.org/10.1093/annonc/mdh216

29. Orel NF, Artamonova EV, Gorbunova VA, et al. Practical recommendations for drug treatment of neuroendocrine neoplasia of the gastrointestinal tract, pancreas and other localizations. Malignant Tumors: Practical Guidelines RUSSCO #3s2, 2021 (vol. 11). 30 (in Russ.)

30. Gill GV, Rauf O, MacFarlane IA. Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J. 1997 Oct 1; 73(864):640–1. doi: https://doi.org/10.1136/pgmj.73.864.640

31. Hirshberg B, Cochran C, Skarulis MC, et al. Malignant insulinoma: Spectrum of unusual clinical features. Cancer. 2005 Jul 15; 104(2):264–72. doi: https://doi.org/10.1002/cncr.21179

32. Goode PN, Farndon JR, Anderson J, et al. Diazoxide in the management of patients with insulinoma. World J Surg. 1986 Aug; 10(4):586–91. doi: https://doi.org/10.1007/BF01655532

33. Ing R, Petrakis L, Ho HC. Evidence against association between wet cerumen and breast cancer. Lancet. 1973; 1(7793):41. doi: https://doi.org/10.1016/s0140-6736(73)91252-x

34. Maggio I, Mollica V, Brighi N, et al. The functioning side of the pancreas: a review on insulinomas. J Endocrinol Invest. 2020 Feb; 43(2):139–48. doi: https://doi.org/10.1007/s40618-019-01091-w

35. Stefanini P, Carboni M, Patrassi N, et al. Beta-islet cell tumors of the pancreas: results of a study on 1,067 cases. Surgery. 1974; 75(4):597-609

36. de Herder WW, Zandee WT, Hofland J. Insulinoma. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; October 25, 2020

37. Gilliaux Q, Bertrand C, Hanon F, et al. Preoperative treatment of benign insulinoma: diazoxide or somatostatin analogues? Acta Chir Belg. 2022; 122(2):136-139. doi: https://doi.org/10.1080/00015458.2020.1765676

38. Niitsu Y, Minami I, Izumiyama H, et al. Clinical outcomes of 20 Japanese patients with insulinoma treated with diazoxide. Endocr J. 2019; 66(2):149-155. doi: https://doi.org/10.1507/endocrj.EJ18-0353

39. Ito T, Igarashi H, Jensen RT. Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract Res Clin Gastroenterol. 2012; 26(6):737-753. doi: https://doi.org/10.1016/j.bpg.2012.12.003

40. Vezzosi D, Bennet A, Courbon F, et al. Short- and long-term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism. Clin Endocrinol (Oxf). 2008; 68(6):904-911. doi: https://doi.org/10.1111/j.1365-2265.2007.03136.x

41. Brown E, Watkin D, Evans J, et al. Multidisciplinary management of refractory insulinomas. Clin Endocrinol (Oxf). 2018; 88(5):615-624. doi: https://doi.org/10.1111/cen.13528

42. Oziel-Taieb S, Maniry-Quellier J, Chanez B, et al. Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature. Front Endocrinol (Lausanne). 2022; 13:860614. Published 2022 Apr 19. doi: https://doi.org/10.3389/fendo.2022.860614

43. Scandellari C, Zaccaria M, De Palo C, et al. The effect of propranolol on hypoglycaemia. Observations in five insulinoma patients. Diabetologia. 1978; 15(4):297-301. doi: https://doi.org/10.1007/BF02573822

44. Filip K, Lewińska A, Adamczyk-Grochala J, et al. 5-Azacytidine Inhibits the Activation of Senescence Program and Promotes Cytotoxic Autophagy during Trdmt1-Mediated Oxidative Stress Response in Insulinoma β-TC-6 Cells. Cells. 2022; 11(7):1213. Published 2022 Apr 4. doi: https://doi.org/10.3390/cells11071213

45. AlJadir S. Insulinoma: literature’s review (part 2). Endocrinol Metab Int J. 2015; 2(4):152-164. doi: https://doi.org/10.15406/emij.2015.02.00031

46. Girot P, Baudin E, Senellart H, et al. Oxaliplatin and 5-Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A Multicenter National Retrospective Study from the French Group of Endocrine Tumors. Neuroendocrinology. 2022; 112(6):537-546. doi: https://doi.org/10.1159/000518650

47. Tran CG, Sherman SK, Chandrasekharan C, et al. Surgical Management of Neuroendocrine Tumor Liver Metastases. Surg Oncol Clin N Am. 2021 Jan; 30(1):39–55. doi: https://doi.org/10.1016/j.soc.2020.08.001

48. Qu Y, Li H, Wang X, et al. Clinical Characteristics and Management of Functional Pancreatic Neuroendocrine Neoplasms: A Single Institution 20-Year Experience with 286 Patients. Kin T, editor. Int J Endocrinol. 2020 Nov 6; 2020:1030518. doi: https://doi.org/10.1155/2020/1030518

49. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: Variables affecting response rates and survival. Cancer. 2005 Oct 15; 104(8):1590–602. doi: https://doi.org/10.1002/cncr.21389

50. Christante D, Pommier S, Givi B, et al. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy. Surgery. 2008 Dec; 144(6):885–94. doi: https://doi.org/10.1016/j.surg.2008.08.037

51. Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for Metastatic Neuroendocrine Liver Tumors: Preliminary Results From a Multi-institutional Experience. Ann Surg. 2008 Jun; 247(6):1029–35. doi: https://doi.org/10.1097/SLA.0b013e3181728a45

52. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients. Am J Clin Oncol. 2008 Jun; 31(3):271–9. doi: https://doi.org/10.1097/COC.0b013e31815e4557

53. Kennedy A, Bester L, Salem R, et al. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford). 2015 Jan; 17(1):29–37. doi: https://doi.org/10.1111/hpb.12326

54. Mayo SC, de Jong MC, Pulitano C, et al. Surgical Management of Hepatic Neuroendocrine Tumor Metastasis: Results from an International Multi-Institutional Analysis. Ann Surg Oncol. 2010 Dec; 17(12):3129–36. doi: https://doi.org/10.1245/s10434-010-1154-5

55. Moug SJ, Leen E, Horgan PG, et al. Radiofrequency Ablation Has a Valuable Therapeutic Role in Metastatic VIPoma. Pancreatology. 2006 Apr; 6(1–2):155–9. doi: https://doi.org/10.1159/000090257

56. Gedaly R. Liver Transplantation for the Treatment of Liver Metastases From Neuroendocrine Tumors: An Analysis of the UNOS Database. Arch Surg. 2011 Aug 1; 146(8):953-8. doi: https://doi.org/10.1001/archsurg.2011.186

57. Treut YPL, Cherqui D, Hannoun L, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg. 1997 Apr; 225(4):355-64. doi: https://doi.org/10.1097/00000658-199704000-00003

58. Olausson M, Friman S, Cahlin C, et al. Indications and Results of Liver Transplantation in Patients with Neuroendocrine Tumors. World J Surg. 2002 Aug 1; 26(8):998–1004. doi: https://doi.org/10.1007/s00268-002-6631-y

59. Zandee WT, Brabander T, Blažević A, et al. Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors. J Clin Endocr Metab. 2019 Apr 1; 104(4):1336–44. doi: https://doi.org/10.1210/jc.2018-01991

60. Strosberg J, Mizuno N, Doi T, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. Clin Cancer Res. 2020 May 1; 26(9):2124–30. doi: https://doi.org/10.1158/1078-0432.CCR-19-3014